Document Detail


Efficacy and Tolerability of long-acting Octreotide in the Treatment of Thymic Tumors: Results of a Pilot Trial.
MedLine Citation:
PMID:  21325939     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVES: Octreotide is a somatostatin analog, long-acting formulations of which have been used experimentally for the treatment of patients with invasive tumors and/or residual disease after conventional therapies. The objective of this retrospective study was to evaluate the efficacy of long-acting octreotide (Sandostatin LAR) for the treatment of thymic tumors, with a primary efficacy end point of progression-free survival. METHODS: Between 1994 and 2010, 44 patients with thymic malignancies were evaluated. Twenty-seven patients underwent an OctreoScan, and 12 OctreoScan-positive patients were treated with long-acting octreotide at a dose of 20 mg, given as an intramuscular injection, every 2 weeks. RESULTS: Treatment with long-acting octreotide gave the following results: 3 cases of partial response (25%), 5 cases of stable disease (42%), and 4 cases of progressive disease (33%), with an average progression-free survival of 8 months (range, 3 to 21). Treatment compliance and tolerability were good for all evaluated patients. CONCLUSIONS: The results of this study confirm the somatostatin receptor as a valid target for the treatment of thymic malignancies. Overall, therapy with long-acting somatostatin analogs seems to be safe and effective.
Authors:
Flavia Longo; Lucilla De Filippis; Andrea Zivi; Domenico Vitolo; Ester Del Signore; Bruno Gori; Daniele Diso; Marco Anile; Federico Venuta; Tiziano De Giacomo; Camillo Furio Coloni
Related Documents :
1730429 - Clinical presentation and management of stage i cervical adenocarcinoma: a 25 year expe...
21310549 - A clinical concept for interfractional adaptive radiation therapy in the treatment of h...
9816009 - Prolonged disease-free period in patients with advanced epithelial ovarian cancer after...
21448449 - Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate...
19804019 - Intraperitoneal chemotherapy of ovarian cancer.
21738039 - Prognostic impact of prechemotherapy serum levels of her2, ca125, and he4 in ovarian ca...
19852529 - Pemetrexed: a review of its use in the management of advanced non-squamous non-small ce...
6455109 - Effective streptozocin therapy for metastatic pancreatic polypeptide apudoma.
22825769 - Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-2-15
Journal Detail:
Title:  American journal of clinical oncology     Volume:  -     ISSN:  1537-453X     ISO Abbreviation:  -     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-2-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Departments of *Clinical Oncology †Pathology ‡Thoracic Surgery, University "La Sapienza", Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Role of Genotype in 104 Cases of Diffuse Large B-Cell Lymphoma Primary of Breast.
Next Document:  Thyroid Transcription Factor-1 in Primary CNS Tumors.